[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glioma-glioblastoma-multiforme\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glioma-glioblastoma-multiforme":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,78,116,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100637209","multicenter-prospective-study-on-mri-ai-model-for-midline-glioma-subtyping-and-prognosis-100637209",false,"NCT07608003","Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:","Application of MRI-Based Artificial Intelligence Models for Preoperative Molecular Subtyping and Prognostic Assessment of Midline Gliomas: A Multicenter Prospective Clinical Study","Inclusion Criteria:\n\n* Patients with diffuse gliomas were pathologically and molecularly diagnosed.\n* The clinical case data of all patients were complete.\n* Patients underwent preoperative MRI examination.\n\nExclusion Criteria:\n\n* The tumor is not located in the intracranial midline.\n* Cases in which MRI were incomplete or with significant noise and artifacts.","ALL",{"count":18,"type":19},500,"ESTIMATED","3 Years","OBSERVATIONAL","A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p\u002F19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.",[24,25,26,27,28,29],"Gliomas Harboring IDH1 and\u002For IDH2 Mutations","Glioma Glioblastoma Multiforme","Glioma of Brainstem","Glioma, Diffuse Midline, H3K27M-mutant","Glioma : Oligodendroglioma or Astrocytoma","Gliomas",[31,32,33,34],"Midline gliomas","Molecular diagnosis","Foundation model","Prognosis prediction","RECRUITING","2026-05-25",{"date":38,"type":39},"2026-05-27","ACTUAL",{"date":41,"type":19},"2026-05-10",{"date":43,"type":19},"2030-12-31",{"name":45,"class":46},"Xiangya Hospital of Central South University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100636554","pet-guided-resection-in-high-grade-gliomas-100636554","NCT07567196","PET-Guided Resection in High-Grade Gliomas","ResPGlioma: Impact of PET-Guided Resection on Survival in High-Grade Gliomas - A Multicenter Prospective Study","ResPGlioma","Inclusion Criteria:\n\n* age ≥18 years\n* high-grade glioma (WHO grade III\u002FIV) diagnosed on MRI\n* provide written informed consent\n\nExclusion Criteria:\n\n* tumors located in the cerebellum, brainstem, or midline.\n* Patients with medical conditions precluding MRI\n* inability to provide written informed consent\n* secondary high-grade gliomas resulting from malignant transformation of a low-grade glioma\n* other primary malignancy within the past five years","18 Years",{"count":58,"type":19},100,"Background: Glioblastoma (GBM) is the most common primary brain tumor in adults, with a poor prognosis despite maximal treatment. Current evidence suggests that supramaximal resection, including non-enhancing FLAIR-hyperintense regions, improves survival. However, the extent of FLAIR resection is often limited by functional constraints and its non-specific nature, as it may represent both tumor infiltration and peritumoral edema. This study explores the role of 18F-DOPA PET in refining supramaximal resection by providing a more specific surgical target beyond contrast-enhancing areas.\n\nObjective: To evaluate the impact of 18F-DOPA PET-guided resection on progression-free survival (PFS) and overall survival (OS) in GBM patients, by comparing outcomes between those undergoing PET-RM integrated resection versus conventional MRI-guided resection.\n\nMethods: ResPGlioma is a multicenter, prospective, non-randomized study conducted at IRCCS Ospedale Policlinico San Martino (Genoa) and AOU Città della Salute e della Scienza (Turin). Patients with newly diagnosed, supratentorial, high-grade gliomas undergo preoperative 18F-DOPA PET and MRI. Surgery follows the principle of maximal safe resection, with postoperative MRI at 48 hours assessing the extent of resection (EOR). To confirm PET resection or non-PET resection status, patients will undergo a postoperative 18F-DOPA PET scan at 30 ± 7 days following surgery, prior to the initiation of chemoradiotherapy. Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.\n\nExpected Outcomes: The authors hypothesize that PET-guided resection improves PFS and OS by enabling a more precise tumor removal beyond contrast-enhancing margins while preserving neurological function. Preliminary data support that PET hypercaptant areas contain viable tumor cells and should be resected. This approach may offer a more accessible yet effective alternative to FLAIR-guided supramaximal resection.",[25,61,62,63],"Glioma, High Grade","Glioma Surgery","Positron-Emission Tomography(PET)",[65,66,67],"glioma","glioblastoma","PET","2026-04-27",{"date":70,"type":39},"2026-05-05",{"date":72,"type":39},"2022-04-01",{"date":74,"type":19},"2029-12-31",{"name":76,"class":46},"Universita degli Studi di Genova",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":91,"conditions":92,"keywords":99,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":115},"100578380","phase-1-safety-and-tolerability-of-tng456-alone-and-in-combination-with-abemaciclib-in-patients-with-solid-tumors-with-mtap-loss-100578380","NCT06810544","Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","A Phase 1\u002F2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","Inclusion Criteria:\n\n* Has a tumor with a confirmed MTAP loss\n* Is ≥18 years of age at the time of signature of the main study ICF\n* Has had progression or an inadequate response to or is intolerant of the approved standard of care therapy, no standard of care therapy exists, or the investigator has determined that treatment with the standard of care therapy is not appropriate.\n* Is able to swallow tablets\n* Adequate Organ function\u002Freserve per local labs\n* Negative serum pregnancy test result at screening\n* Has an ECOG performance status score of 0 to 1\n* Has measurable disease based on RECIST v1.1 or a confirmed glioblastoma (IDH-wildtype) with radiographic evidence of disease progression or recurrence defined by RANO 2.0.\n* Has an ECOG performance score of 0 to 1 or for GBM has a Karnofsky performance status score ≥70.\n\nExclusion Criteria:\n\n* A female patient is who is pregnant or breastfeeding\n* Has impaired GI function or disease that may significantly alter the absorption of oral study treatment(s)\n* Has an active infection requiring systemic therapy\n* Has received prior treatment with a PRMT5 inhibitor or a MAT2A inhibitor\n* Patients in the expansion receiving the combination therapy that have received prior treatment with a CDK4\u002F6 inhibitor\n* Clinically relevant cardiovascular disease\n* Has a prior or ongoing clinically significant illness may affect the safety of the patient, impair the assessment of study results or compliance with the protocol",{"count":86,"type":19},191,"INTERVENTIONAL",[89,90],"PHASE1","PHASE2","This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.",[93,25,94,95,96,97,98],"Non Small Cell Lung Cancer","Glioma, Malignant","Solid Tumor","Non-Small Cell Adenocarcinoma","Lung Cancer","Brain Tumor",[100,101,102,103,104],"MTAP","PRMT5 inhibitor","CDK 4\u002F6","abemaciclib","Tango","2026-04-10",{"date":107,"type":39},"2026-04-13",{"date":109,"type":39},"2025-03-24",{"date":111,"type":19},"2027-09-30",{"name":113,"class":114},"Tango Therapeutics, Inc.","INDUSTRY",15,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":87,"phases":126,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":77},"100445904","wbsi-guided-personalized-delivery-of-ttfields-100445904","NCT05086497","WBSI Guided Personalized Delivery of TTFields","Whole-Brain Spectroscopy Guided Personalized Mapping of Transducer Arrays for Glioblastoma Patients Receiving Tumor Treating Fields","Inclusion Criteria:\n\n* Adult population ≥ 22 years\n* Histologically confirmed diagnosis of GBM or molecular GBM according to c-IMPACT NOW criteria\n* Have undergone maximal safe surgical resection followed by either standard full course radiation of 6000 cGy in 6 weeks or a hypofractionated course of 4000 cGy in 3 weeks\n* 3 Harboring any genotype profiles (MGMT promoter methylation or unmethylation and\u002For isocitrate dehydrogenase (IDH) mutant or IDH wild-type)\n* Possessing adequate hematological, hepatic and renal functions\n* Willingness to receive TTFields\n\nExclusion Criteria:\n\n* Presence of infra-tentorial GBM\n* Pregnancy\n* Significant co-morbidities at baseline which would prevent maintenance TMZ treatment\n* Active implanted medical device, a skull defect (such as missing bone with no replacement) or bullet fragments. Examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators,pacemakers, defibrillators and programmable shunts. , other implanted electronic devices in the brain.\n* Sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.\n* Presence of significant hemorrhage in and around the tumor bed that may potentially degrade the image quality.","22 Years",{"count":125,"type":19},155,[127],"NA","This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that utilizes - tumor treating fields (TTFields), (aka, electrical therapy), which has shown to improve overall survival in large multi-center trials. As a part of this study, participants will either receive Optune with \"standard array mapping\" (based on regular contrast enhanced MRI) or an \"alternative (more precise) array mapping\" based on sophisticated state of the art MRI techniques including \"whole brain spectroscopy\". Whole brain MRI spectroscopy provides additional metabolic information to map out the full extent of tumor spreading within the brain (far beyond from what is seen on regular MRI), by identifying certain metabolites that are present in cancer cells versus healthy tissue. This study is being performed to show whether alternative array mapping improves treatment outcomes, as opposed to the standard array mapping, by maximizing delivery of TTFields dose, thereby achieving more effective tumor cell killing, decreasing the rate of local recurrence, and improving the overall survival as well as quality of life measures.",[130,25,131],"GBM","Tumor, Brain","2026-03-09",{"date":134,"type":39},"2026-03-11",{"date":136,"type":39},"2023-01-15",{"date":138,"type":19},"2026-06-30",{"name":140,"class":46},"Abramson Cancer Center at Penn Medicine",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":20,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":87,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":47},"100568933","phase-2-injection-of-active-allogeneic-natural-killer-cells-in-patients-with-gliomas-100568933","NCT06687681","Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas","Efficacy of the Intrathecal Injection of Active Allogeneic Natural Killer Cells in Patients With High-grade Gliomas; A Multi-center Phase II Clinical Trial","Inclusion Criteria: New diagnosed patients with grade 3 or 4 brain tumor, based on WHO classification, which are included in the one of the following conditions: • Astrocytoma, IDHmutant • Oligodendroglioma, IDH-mutant • Glioblastoma, IDH-wild type • Diffuse midline glioma • Diffuse hemispheric glioma • Diffuse pediatric-type high-grade glioma, IDH-wild type Age range of 3 to 60 years old both sex Lansky\u002FKarnofsky performance score above 60 Obtained informed consent of patients or parents or legal attendance in cases of pediatrics Hemoglobin above 10 gr\u002FdL of blood Absolute granulocyte count (AGC) above 500 per microliter of blood Platelet count above 50000 per microliter of blood INR below 2 and PTT less than 1.5 times of maximum normal value Plasma bilirubin level less than 1.5 times of maximum normal value Plasma hepatic transaminases (ALT and AST) level less than 3 times of maximum normal value Plasma creatinine level less than 1.5 times of maximum normal value -\n\nExclusion Criteria: Evidence of radio necrosis in MRI or MRS Intolerance of new treatment due to emergency condition History of other malignancies History of any immunodeficiency diseases or any immune compromising conditions Rupture of cerebral shunt or unable to perform a lumbar puncture Pregnancy History of uncontrolled chronic diseases such as: Diabetes, CHF, liver cirrhosis, CKD, etc\n\n\\-","70 Years",{"count":150,"type":19},40,[90],"Gliomas are the most common malignant brain tumors, which are often associated with high-grade tumors characterized by an inferior prognosis and low patient survival rates in both children and adults. Surgical removal and tumor resection are the primary treatment approaches for gliomas. In such cases, whole-brain radiation therapy is also employed as a therapeutic option, which itself has significant side effects, and studies have shown limited impact on improving patient survival. Targeted therapy and recently investigated approaches such as targeted therapy have shown some tumor regression, but in most cases, tumor recurrence has been observed after initial regression. Therefore, they have a limited impact on prolonging patient survival. Immunotherapy, particularly immunotherapy with specific immune cells, can effectively identify and eliminate cancer cells and has been utilized as a new approach in the past two decades, especially in cancers where conventional methods have limited success. Among the effective immunotherapy methods, using natural killer cells (NK cells) can be one of the promising approaches. Currently, phase I clinical trials have been conducted by our research group in patients with gliomas.",[25,154],"High Grade Glioma (III or IV)",[156,157,158,66,159],"natural killer cells","Brain glioma","NK cells","high grade gliomas","2025-04-05",{"date":162,"type":39},"2025-04-09",{"date":164,"type":39},"2024-11-25",{"date":166,"type":19},"2027-11-25",{"name":168,"class":114},"Marzieh Ebrahimi"]